Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients

恶性胸膜间皮瘤患者血清趋化因子 CCL2 水平升高

阅读:11
作者:Takumi Kishimoto, Nobukazu Fujimoto, Takeshi Ebara, Toyonori Omori, Tetsuya Oguri, Akio Niimi, Takako Yokoyama, Munehiro Kato, Ikuji Usami, Masayuki Nishio, Kosho Yoshikawa, Takeshi Tokuyama, Mouka Tamura, Yoshifumi Yokoyama, Ken Tsuboi, Yoichi Matsuo, Jiegou Xu, Satoru Takahashi, Mohamed Abdelgied,

Background

Malignant pleural mesothelioma (MPM) is a debilitating disease of the pleural cavity. It is primarily associated with previous inhalation of asbestos fibers. These fibers initiate an oxidant coupled inflammatory response. Repeated exposure to asbestos fibers

Conclusions

Our findings are consistent with the premise that the CCL2/CCR2 axis and myeloid-derived cells play an important role in MPM and disease progression. Therapies are being developed that target CCL2/CCR2 and tumor resident myeloid cells, and clinical trials are being pursued that use these therapies as part of the treatment regimen. The results of trials with patients with a similar serum CCL2 pattern as MPM patients will have important implications for the treatment of MPM.

Methods

The present study was carried out with 50 MPM patients and 356 subjects who were possibly exposed to asbestos but did not have disease symptoms and 41 healthy volunteers without a history of exposure to asbestos. The levels of CCL2 in the serum of the study participants was determined using ELISA.

Results

Levels of CCL2 were significantly elevated in the serum of patients with advanced MPM. Conclusions: Our findings are consistent with the premise that the CCL2/CCR2 axis and myeloid-derived cells play an important role in MPM and disease progression. Therapies are being developed that target CCL2/CCR2 and tumor resident myeloid cells, and clinical trials are being pursued that use these therapies as part of the treatment regimen. The results of trials with patients with a similar serum CCL2 pattern as MPM patients will have important implications for the treatment of MPM.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。